News
Media
Conferences
Publication
Job Board
CME/CE
Partners
Editorial
Resources
Subscribe

Spotlight -

Long-Acting Injectable Therapy in the Management of Adult Patients with Schizophrenia|

Major Depressive Disorder

|Videos|March 15, 2021

Info Flow: The Neuronal Level

Author(s)John J. Miller, MD

Information is buzzing around in the brain, but how does it transmit across neurons?

John J. Miller, MD, breaks down informational flow across neurons.

Dr Miller is medical director, Brain Health, Exeter, NH; editor in chief, Psychiatric TimesTM; staff psychiatrist, Seacoast Mental Health Center, Exeter, NH; consulting psychiatrist, Exeter Hospital, Exeter, NH; consulting psychiatrist, Insight Meditation Society, Barre, MA.

Newsletter

Receive trusted psychiatric news, expert analysis, and clinical insights — subscribe today to support your practice and your patients.

Related Content

Psychiatric Times Experts Weight in on FDA Advisory Decision for PTSD

Psychiatric Times Experts Weigh in on FDA Advisory Decision for PTSD

ByJohn J. Miller, MD,Michael Asbach, DMSc, PA-C, Psych-CAQ,Erin Crown, MHS, PA-C, Psych-CAQ,Leah Kuntz

July 18th 2025

New Africa /Adobestock

Poster at APA Annual Meeting Explores the Use of GLP-1 Agonists for Antipsychotic-Associated Metabolic Issues

ByAmir Meftah, MD,Heidi Anne Duerr, MPH

May 18th 2025

How effective are these agents for AUD treatment? An expert shares highlights from his 2024 ASCP Annual Meeting Pharmaceutical Pipeline Update presentation.

An Update on GLP-1 Receptor Agonists as Pharmacotherapies for AUD

ByMehdi Farokhnia, MD, MPH

June 5th 2024

Erin Crown, MHS, PA-C, shares her thoughts on ASCP, the annual meeting, and more.

Research and Opportunities at the 2024 ASCP Annual Meeting

ByErin Crown, MHS, PA-C, Psych-CAQ

May 30th 2024

Anita H. Clayton, MD, gives a preview of her upcoming poster presentation at the 2024 ASCP Annual Meeting.

Early Improvement of Symptoms in Bipolar 1 Depression

ByAnita H. Clayton, MD

May 30th 2024

Latest CME

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

PER Psych Summit: Integrating Shared Decision-Making Into Management Plans for Patients With Schizophrenia

Sanjai Rao, MD, DFAPA; Dawn I. Velligan, PhD

Southern Florida Psychiatry Conference

In-Person Event

Southern Florida Psychiatry Conference

November 21-22, 2025

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Case-based Simulation

SimulatED™: Understanding the Role of Genetic Testing in Patient Selection for Anti-Amyloid Therapy

Nicholas Doher, DO; Babak Tousi, MD

Real Psychiatry 2026

In-Person + Virtual Event

Real Psychiatry 2026

January 23-24, 2026

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Managing Negative Symptoms of Schizophrenia: Can Prescription Digital Therapeutics Make an Impact?

Michael Asbach, DMSc, PA-C; Erin Crown, MHS, PA-C, Psych-CAQ

Optimizing Care for Patients With Tardive Dyskinesia

Optimizing Care for Patients With Tardive Dyskinesia

Amber Hoberg, MSN, APRN, PMHNP-BC; Erin Crown, PA-C, Psych-CAQ

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Stabilize and Thrive: Prioritizing Patient Success Through Novel Therapeutic Management in Schizophrenia

Jonathan Meyer, MD; Jacob Hanaie, PharmD, APh, BCPP; Sanjai Rao, MD, DFAPA

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(CME Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

(Pharmacist Track) SoCal Psych 2025: Overcoming Barriers to Long-Acting Injectable Agents in Schizophrenia

Gus Alva, MD, DFAPA; Ilan Melnick, MD

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Live Expert Illustrations & Commentary™: Visualizing Novel Therapeutic Targets for Patients with Major Depressive Disorder

Jason Kellogg, MD; Gus Alva, MD, DFAPA; Melanie Barrett, MD; Yvette Elpidio, MSN, FNP-C

Trending on Psychiatric Times

FDA Approves Caplyta for Adjunctive Treatment of Major Depressive Disorder

The Spiritual Determinants of Health and Mental Health

Caplyta FDA Approval: Benefits for Patients, With Roger McIntyre, MD

Bridging the Categorical-Dimensional Divide: Exploring the PRiSM Diagnostic Instrument

Combination Therapy With TMS and Ketamine for Depression, Neuropathic Pain, and Substance Use Disorder: A Network-Based Approach

© 2025 MJH Life Sciences^®

All rights reserved.